Professional Documents
Culture Documents
To Analyze Market Potential of Injectable Drugs in Malegaon City
To Analyze Market Potential of Injectable Drugs in Malegaon City
Entitled
submitted to:
ANNAMALAI UNIVERSITY,
CHENNAI
Through
even as they threaten the status quo. Yes, old businesses die and new ones
imperatives – those who can deliver what people are ready to buy.
can be. That is what the science of medicine is all about. Pharmaceutical
companies control 70% of the market with market leader holding nearly 7%
INTRODUCTION
1. INTRODUCTION :
The Pharmaceutical Industry, has had its beginning in the middle of the
penicillin & other antibiotics which have increased the popularity of the
Most major pharmaceutical companies were founded in the late 19th and
early 20th centuries, although it is only since the 1950's the industry got
The industry remained relatively small scale until a long period of scientific
companies.
There are currently more than 200 major pharmaceutical companies. As in
the tension between the affordability of new medicines and their benefits
Industry revenues
2004 global dollar volume was $550 billion, a 7% increase over 2003—
$235.4 billion, a growth rate of 8.3% compared with 11.5% growth from
2002 to 2003. The United States accounts for 46% of the world's
pharmaceutical market.
According to Teradata Magazine, "By 2007, $40 billion in U.S. sales will be
broader look across the industry, no fewer than 19 blockbuster drugs are
expected to hit patent crisis by 2008. Analysis suggests that 150 mid-
sized new compounds will be needed by 2007-2008 in the U.S. alone to plug
this gap."
AN OVERVIEW
Playing a key role in promoting and sustaining development in the vital field
chemicals, tablets, capsules, orals and injectibles. There are about 250
large units and about 8000 Small Scale Units, which form the core of the
i.e., medicines ready for consumption by patients and about 350 bulk drugs,
i.e., chemicals having therapeutic value and used for production of
pharmaceutical formulations.
licensing for most of the drugs and pharmaceutical products has been done
away with. Manufacturers are free to produce any drug duly approved by
the pharmaceutical industry in India has low costs of production, low R&D
14 percent per year. It is one of the largest and most advanced among
exceed Rs260 billion in the financial year 2002, which accounts for
merely 1.3% of the global pharmaceutical sector. Of this, bulk drugs will
Rs87 bn.
to offset loss of new product options, improve their R&D efforts and
Research and development has always taken the back seat amongst
future, Indian companies will have to refocus and invest heavily in R&D.
margins of players vary widely in both domestic and export sales due to
many factors.
a) Domestic Trade
More than 85% of the formulations produced in the country are sold in
b) Exports
the tune of Rs87bn, of which formulations contribute nearly 55% and the
rest 45% comes from bulk drugs. In financial year 200, exports grew by
against the last year exports. Amongst the total exports of India, the
recognition to all new chemical entities (NCEs) i.e., bulk drugs developed
got a boost when Dr. Reddy's licensed two of its anti-diabetic molecules
to Novo Nordisk and when Ranbaxy licensed its Novel Drug Delivery
future benefiting the MNCs. New legislation is also expected in the OTC
segment increasing the number of brands in the Over the Counter (OTC)
segment.
Pharma, and Dr. Reddy's are increasingly focusing on tapping the U.S.
life expectancy and health all over the world are the result of a steadily
for some of the diseases peculiar to a tropical country like India and also
for finding solutions for unmet medical needs. Industrial R & D groups
can carry out limited primary screening to identify lead molecules or even
that India is entering into the Patent protection area, many companies
(CROs).
various drug molecules. Some MNCs are already sourcing these services
deduction for R&D expense upto 150%. These R&D companies will also
GROWTH INDICATORS
(Rs. crores)
1965-66 1999-00
Capital Investment 140 2,500
Production:
Formulations 150 15,960
Bulk Drugs 18 3,777
Import 8.20 3,441
Export 3.05 6,631
R&D Expenditure 3 320
Number Of Units
Years Units
1969-70 2,257
1979-80 5,156
1989-90 16,000
1999-00 20,053
Investment
Years (Rs. crores)
1973 225
1977 450
1979 500
1982 600
1985 650
1988 800
1993 1,060
1994 1,200
1995 1,380
1996 1,600
1997 1,840
1998 2,150
1999 2,500
Production - Bulk Drugs
Years (Rs. crores)
1980-81 240
1981-82 289
1982-83 345
1983-84 355
1984-85 377
1985-86 416
1986-87 458
1987-88 480
1988-89 550
1989-90 640
1990-91 730
1991-92 900
1992-93 1,150
1993-94 1,320
1994-95 1,518
1995-96 1,822
1996-97 2,186
1997-98 2,623
1998-99 3,148
1999-00 3,777
Production - Formulations
Years (Rs. crores)
1980-81 1,200
1981-82 1,434
1982-83 1,660
1983-84 1,760
1984-85 1,827
1985-86 1,945
1986-87 2,140
1987-88 2,350
1988-89 3,150
1989-90 3,420
1990-91 3,840
1991-92 4,800
1992-93 6,000
1993-94 6,900
1994-95 7,935
1995-96 9,125
1996-97 10,494
1997-98 12,068
1998-99 13,878
1999-00 15,960
Exports (Rs. Crores)
Years Finished % of Bulk Drugs % of Total
Formulations Total Including Total
Quinine Salts
1980-81 35.10 (76) 11.28 (24) 46.38
1981-82 69.34 (82) 15.45 (18) 84.79
1982-83 54.60 (83) 11.34 (17) 65.94
1983-84 61.46 (77) 18.46 (23) 79.92
1984-85 99.50 (77) 29.25 (23) 128.75
1985-86 106.59 (76) 33.36 (24) 139.95
1986-87 102.12 (54) 87.16 (46) 189.28
1987-88 88.25 (39) 139.71 (61) 227.96
1988-89 157.29 (39) 242.87 (61) 400.16
1989-90 314.20 (47) 350.50 (53) 664.70
1990-91 371.40 (47) 413.40 (53) 784.80
1991-92 558.50 (44) 722.60 (56) 1,281.10
1992-93 965.50 (70) 409.50 (30) 1,375.00
1993-94 1,310.80 (71) 530.80 (29) 1,841.60
1994-95 1,505.50 (66) 760.10 (34) 2,265.60
1995-96 2,044.80 (64) 1,132.90 (36) 3,177.70
1996-97 2,509.20 (61) 1,581.10 (39) 4,090.30
1997-98 3,180.00 (59) 2,173.00 (41) 5,353.00
1998-99 3,194.90 (54) 2,764.10 (46) 5,959.00
1999-00 - - - - 6,631.00
Imports - Composition
Years Bulk Formulations Intermediates, Total
Drugs Chemicals, Solvents &
others
1980-81 87.24 9.62 15.68 112.54
1981-82 105.06 1.93 29.34 136.33
1982-83 115.55 5.41 27.52 148.48
1983-84 123.06 3.43 36.85 163.34
1984-85 178.41 10.17 27.05 215.63
1985-86 208.13 15.82 43.44 267.39
1986-87 207.49 21.84 58.26 287.59
1987-88 234.13 21.44 93.87 349.44
1988-89 328.35 35.43 83.13 446.91
1989-90 425.64 55.09 171.39 652.12
1990-91 322.57 84.94 196.49 604.00
1991-92 458.51 96.12 252.75 807.38
1992-93 508.39 119.51 509.48 1,137.38
1993-94 612.74 138.33 415.46 1,166.53
1994-95 811.43 173.02 384.27 1,368.72
1995-96 1,630.00 270.00 505.00 2,405.00
1996-97 1,705.00 345.00 555.50 2,605.50
1997-98 1,827.00 430.00 611.00 2,868.00
1998-99 1,918.00 540.00 670.00 3,128.00
1999-00 2,025.00 680.00 736.00 3,441.00
CHAPTER NO : 2
OBJECTIVES, HYPOTHESES,
RESEARCH METHODOLOGY,
Malegaon City.
Analysis Target
Markets
Planning
Mktg
Implement- Mktg Marketing Channels
Distributing decision Research
ation Competitors
infn. support
Control Analysis Public
Macro Envt
Malegaon City.
injectable market.
of ASCENT BIOCARE .
2.2. HYPOTHESES :
A Hypothesis is a statement of a tentative supposition or a possible
depending on PRICE.
of ASCENT BIOCARE .
2.3. RESEARCH METHODOLOGY :
Marketing Research is a systematic gathering, recording & analysis of
data about the problems relating to the marketing of goods & services &
the product performance of the firm in terms of turn over, profits, and
below:
The problem & objective of the study has been already defined under
This stage spells out how to achieve the stated Research objectives. The
Design.
The Research design here calls for gathering two types of data to
personal interviews.
technique to get a preliminary sense of how people feel about the topic in
question.
ii) A sample was taken for the purpose of achieving the research
objective.
the study.
taken.
Sampling Method.
d) Research Instrument : A structured Questionnaire was used as an
circulating into the field. There are both closed end questions &
open-end questions.
internal sources:
Internet websites.
number of days for entire operation & the pattern to be used for
This stage deals with extracting pertinent findings from the collected
data. The collected data are processed, organized & arranged (tabulated)
making process.
STEP 5 : PRESENTING OF FINDINGS :
The study was completed in two months which is inadequate for the
The result of the study may not be applied to another company in the
same industry.
CHAPTER NO : 3
COMPANY PROFILE
INTRODUCTION :
established in 2007.
It has acquired a great success in its previous endeavours & has won the
lion’s share in Southern markets of India. They are now pursuing their
see to it that their merchandise shall be of a quality that will merit the
Standing in the trade for many years we have in our credit a most
The plant is well equipped with the state-of-the-Art & highly automated
Pyrogen / LAL Test, Sterility Test, H.P.L.C. G.L.C., T.L.C. & others. Thus
they provide unique sense of relief & safety to the user. The facilities
for Quality Control & Quality Assurance are in line with production. The
The organization has always enjoyed a good reputation in the market due
Personnel.
PRODUCTION CAPACITY :
Major raw materials are available indigenously & are procured from local
manufactures & suppliers. The company does not foresee any problem
TRANSPORT :
Hajibhai Transport & Khandesh Speed Carriers etc. having their depots
skilled & unskilled employees over & above field force for marketing /
manpower.
highly qualified and experienced staff for supervising & conducting the
Assurance Sections.
BP / USP Standards.
Inj. DXM is the most widely used cortico – steroid. Inj. DXM meets any
emergency with intensified potency & strikingly rapid corticosteroid action,
thus ensuring speedy reversal of the situation in the patients favour.
Inj. DXM is effective in :
Allergic reactions
Acute dermatological disorders
Rheumatic disorders
Acute stage of infections, etc.
Inj. A ‘D’ LOC is the perfect locking agent for problems of ACIDITY &
ULCERS.
2) ATROPINE SULPHATE
0.6 mg/ml – 1ml ampoule / 10ml Vial.
Rope in the life with ASCENT BIOCARE’s Atropine
3) INJ. SODIUM BICARBONATE
7.5 % - 10 ml Ampoules
5) INJ. AMINOPHYLLINE
25 mg / ml – 10 ml Ampoules
Clear the airway with ASCENT BIOCARE’s Aminophylline
6) INJ. CYNOCOBALAMIN
500mcg/ml – 30 ml Vial
CHAPTER NO : 4
OF RESEARCH DATA
4. INTERPRETATION & ANALYSIS OF RESEARCH DATA :
The data obtained from the survey of retailers through the structured
generated
TABLE 4.1
45
NO. OF RETAIL COUNTERS 40
35
NO. OF RETAIL COUNTERS
30
25
20
15
10
5
0
UNICHEM
EMCURE
ETHNOR
OTHERS
PFIZER
IND-SWIFT
FDC LTD.
LUPIN
GENO
DR. REDDY’S
GERMAN
IPCA
DWD
WOCKHARDT
CIPLA
ASCENT
ALKEM
CADILA
VHB
USV
GLAXO
RANBAXY
COMPANIES
INTERPRETATION :
The analysis of above tabulation shows that in Malegaon city the company
supplying the greater volume of injectables is M/S. ASCENT BIOCARE.
-----------------------------------------------------------------------------------
OTHERS: It includes a number of companies that cater only limited number of retailers
RANBAXY
CIPLA
NO. OF RETAIL COUNTERS
40 FDC LTD.
30 IND-SWIFT
DWD
20
GERMAN REMEDIES
10
IPCA
0 WOCKHARDT
EMCURE
INTERPRETATION :
The analysis of above tabulation shows that the major & close competitors
of M/S. ASCENT BIOCARE are Cadila Pharmaceuticals, Ranbaxy Labs ltd,
Cipla Ltd, & FDC ltd in Malegaon City
TABLE NO.:4.3
CUSTOMERS OF INJECTABLES
NO. OF CUSTOMERS 45
40
35
30
25
20
15
10
5
0
ORTHO. SURGEON
GEN. SURGEONS
NEUROLOGISTS
CARDIOLOGISTS
E.N.T. SPECIALIST
PAEDIATRICIANS
OPTHALMALOGIST
DENTISTS
OPTICIANS
PSYCHATRIST
GYNAEC
G.P.s
N.A.
SPECIALIZATION
INTERPRETATION :
20
18
RETAIL SERVICE
16
14
12
10
8
6
4
2
0
CLINICS (NOT
OTHERS
MANGOLEKAR
MEDICARE
HUSSEINI
ACCIDENT
LIFECARE
BURUDE
HOSPITALS)
NOOR
N.A.
MAMCO
M.J.
SITABAI
NAVJEEVAN
KARWA
VAIDYA
PATIL
HOSPITALS
INTERPRETATION :
The analysis of above tabulation shows that the hospital with greater
consumption of injectable products is M.J.Hospital.
25
20
SHARE
15
10
5
0
EMCURE
IND-SWIFT
OTHERS
PHARMA
PHARMA
N.A.
ASCENT
RANBAXY
CADILA
IPCA
COMPANY NAME
INTERPRETATION :
The analysis of above tabulation shows that M/S. ASCENT BIOCARE enjoys
major share of injectable market in Malegaon City.
------------------------------------------------------------------------------------
Others : It includes those companies whose products are in demand by a negligible number
of retailers.
N.A. : it includes those retailers who do not supply injectable range of products.
04%
BELOW 50%
50 % - 60 %
24%
60 % - 70 %
70 % - 80 %
ABOVE 80 %
N.A.
72%
INTERPRETATION :
COMPANY IMAGE
32% PRICE
QUALITY
SPECIAL SCHEMES
N.A.
57%
INTERPRETATION :
The analysis of above representation shows that the major features that
influence the demand of injectables products is PRICE.
INTERPRETATION :
NO. OF DOCTORS
30 25
25
20 16 15
15 12
10 6 5
3 2 3
5
0
GEN. SURGEONS
ORTHOPAEDIC
CARDIOLOGISTS
OPTHALMALOGISTS
PAEDIATRICIANS
GYNAECOLOGIST
OTHERS
G. P.s
N.A.
SURGEON
DOCTORS
INTERPRETATION :
RETAIL SERVICE
14 11 12
12 10
10
8
6 3 3 3 4
4 2 2
2
0
OTHERS
MEDICARE
ACCIDENT
BURUDE
CLINICS
NOOR
NAVJEEVAN
N.A.
M.J
PATIL
HOSPITALS
INTERPRETATION :
The analysis of above representation shows that the hospital with greater
consumption of ASCENT BIOCARE injectable products is M.J. HOSPITAL.
QUALITY
13%
2% REASONABLE PRICE
2% 35%
EASY AVAILABILITY
FAST ACTION
22%
PACKING
26%
N.A.
INTERPRETATION :
SAMPLES FOR
DOCTORS
3%
11% REVISION OF
PRICELIST
34%
15% NO SUGGESTIONS
INCREASE PRODUCT
RANGE
16%
21% ARRANGE PARTIES
INTERPRETATION :
The analysis of above representation shows that most of the retailers feel
that the sales volume of ASCENT BIOCARE products can be improved by
MAINTAINING A REGULAR SUPPLY to meet the demand.
4.2. MARKET PERFORMANCE OF ASCENT BIOCARE :
& 4.10)
ASCENT BIOCARE are General Practitioners. (see graph 4.3 & 4.9)
quality. These are the same features that influence the demand of
New and old users are presented with motivational gifts &
customers.
The middle men are motivated through price – off offers, quantity
off offers, gift etc. they are also given festive offers.
targets achieved.
retailers :
CONCLUSION &
RECOMMENDATION
5. CONCLUSION & RECOMMENDATIONS :
The diagnosis of the study helps to bring out the conclusions and
5.1. CONCLUSIONS :
following conclusions have been put forward for the effective role of
ASCENT BIOCARE .
depending on PRICE.
ASCENT BIOCARE .
4) ASCENT BIOCARE suffers from the problem of not
upon only on a small range of its products. Thus, many products have
5.2. RECOMMENDATIONS :
synchronized.
14. What are the factors that influence the demand of the product?
15. Do you use injectable range of products manufactured by ASCENT BIOCARE ?
16. Which molecule of ASCENT BIOCARE is in greater demand?
17. Who are the major customers of ASCENT BIOCARE prodcts?
18. Which Hospital has greater demand of ASCENT BIOCARE prodcts?
19. What are the features of ASCENT BIOCARE products that encourage its
demand?
20. What are the benefits provided by other companies?
21. Any suggestions to increase the sale volume of ASCENT BIOCARE products?
--------------------------------------------------------------------------------------
practices
Background)
www.sharekhan.com
INDEX
TITLE PAGE NO
1) Introduction 1
16
3) Company Profile 23
48
APPENDICES: 51
a) Questionnaire
52
b) Bibliography
53
LIST OF FIGURES
TITLE PAGE NO
1) Introduction 1
original research work and the same has not been previously submitted
This project report could not have been completed without guidance our
Also I express my sincere thanks and gratitude to all dealers for their